Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 8

finance.yahoo.com

The FDA has placed a partial clinical hold on Gilead Sciences Inc’s (NASDAQ: GILD) studies evaluating the combination of magrolimab plus azacitidine. Due to